EMA Authorised: Dyrupeg (pegfilgrastim) — CuraTeQ Biologics s.r.o

View source ↗

Summary

EMA authorises Dyrupeg (pegfilgrastim) by CuraTeQ Biologics for use in neutropenia and cancer indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Neutropenia

Drugs mentioned

• Dyrupeg (pegfilgrastim)

Snippet

Status: Authorised. Therapeutic area: Neutropenia;Cancer. MAH: CuraTeQ Biologics s.r.o. Decision date: 11/08/2025